Oxymetazoline inhibits osmotic water permeability (Pf) in the rat cortical collecting duct (CCD) and inner medullary collecting duct (IMCD)

C. Hébert, Alexander Rouch, L. Kudo

Research output: Contribution to journalArticle

Abstract

The objective of this study was to determine if the alpha-2 (α2) adrenoceptor agonist oxymetazoline would inhibit Pf in collecting duct nephron segments. The isolated perfused tubule technique was used to determine Pf by measuring net fluid flux in the presence of a lumen-to-bath osmotic gradient and by calculating Pf via standard equations. One set of studies was conducted using CCDs isolated from Sprague-Dawley rat kidneys and another set was conducted in terminal IMCDs isolated from Wistar rat kidneys. Experimental agents were added to the bathing solution, and all experiments were conducted at 37°C. Arginine vasopresein (AVP) at 220pM was used to increase Pf. Oxymetazoline and the α2 antagonist atipamezole were used at 1 μM. The sequence of periods and the results (Pf, μm/sec, mean±se) are shown below. Control AVP AVP+Oxy AVP+Oxy+Ati CCDs (n=7) -16±35 748±92* 295±113† 580±93® IMCPs (n=5) 3±1 140±6* 32±3* 76±3* *, † and ® - significantly different from the previous period (p<.001), (p<.005), and (p<.05), respectively. Oxy - oxymetazoline, Ati - atipamezole. We conclude that oxymetazoline, a partial α2A adrenoceptor agonist, inhibits AVP-stimulated Pf in the rat CCD and IMCD.

Original languageEnglish
JournalFASEB Journal
Volume11
Issue number3
StatePublished - 1 Dec 1997

Fingerprint

Oxymetazoline
Ducts
arginine
Arginine
Rats
Permeability
permeability
Water
rats
adrenergic receptors
Charge coupled devices
water
Adrenergic Receptors
agonists
kidneys
Kidney
nephrons
Nephrons
Baths
Sprague Dawley Rats

Cite this

@article{2ba9b49de78f47538b9075ae094841ad,
title = "Oxymetazoline inhibits osmotic water permeability (Pf) in the rat cortical collecting duct (CCD) and inner medullary collecting duct (IMCD)",
abstract = "The objective of this study was to determine if the alpha-2 (α2) adrenoceptor agonist oxymetazoline would inhibit Pf in collecting duct nephron segments. The isolated perfused tubule technique was used to determine Pf by measuring net fluid flux in the presence of a lumen-to-bath osmotic gradient and by calculating Pf via standard equations. One set of studies was conducted using CCDs isolated from Sprague-Dawley rat kidneys and another set was conducted in terminal IMCDs isolated from Wistar rat kidneys. Experimental agents were added to the bathing solution, and all experiments were conducted at 37°C. Arginine vasopresein (AVP) at 220pM was used to increase Pf. Oxymetazoline and the α2 antagonist atipamezole were used at 1 μM. The sequence of periods and the results (Pf, μm/sec, mean±se) are shown below. Control AVP AVP+Oxy AVP+Oxy+Ati CCDs (n=7) -16±35 748±92* 295±113† 580±93{\circledR} IMCPs (n=5) 3±1 140±6* 32±3* 76±3* *, † and {\circledR} - significantly different from the previous period (p<.001), (p<.005), and (p<.05), respectively. Oxy - oxymetazoline, Ati - atipamezole. We conclude that oxymetazoline, a partial α2A adrenoceptor agonist, inhibits AVP-stimulated Pf in the rat CCD and IMCD.",
author = "C. H{\'e}bert and Alexander Rouch and L. Kudo",
year = "1997",
month = "12",
day = "1",
language = "English",
volume = "11",
journal = "FASEB Journal",
issn = "0892-6638",
publisher = "FASEB",
number = "3",

}

TY - JOUR

T1 - Oxymetazoline inhibits osmotic water permeability (Pf) in the rat cortical collecting duct (CCD) and inner medullary collecting duct (IMCD)

AU - Hébert, C.

AU - Rouch, Alexander

AU - Kudo, L.

PY - 1997/12/1

Y1 - 1997/12/1

N2 - The objective of this study was to determine if the alpha-2 (α2) adrenoceptor agonist oxymetazoline would inhibit Pf in collecting duct nephron segments. The isolated perfused tubule technique was used to determine Pf by measuring net fluid flux in the presence of a lumen-to-bath osmotic gradient and by calculating Pf via standard equations. One set of studies was conducted using CCDs isolated from Sprague-Dawley rat kidneys and another set was conducted in terminal IMCDs isolated from Wistar rat kidneys. Experimental agents were added to the bathing solution, and all experiments were conducted at 37°C. Arginine vasopresein (AVP) at 220pM was used to increase Pf. Oxymetazoline and the α2 antagonist atipamezole were used at 1 μM. The sequence of periods and the results (Pf, μm/sec, mean±se) are shown below. Control AVP AVP+Oxy AVP+Oxy+Ati CCDs (n=7) -16±35 748±92* 295±113† 580±93® IMCPs (n=5) 3±1 140±6* 32±3* 76±3* *, † and ® - significantly different from the previous period (p<.001), (p<.005), and (p<.05), respectively. Oxy - oxymetazoline, Ati - atipamezole. We conclude that oxymetazoline, a partial α2A adrenoceptor agonist, inhibits AVP-stimulated Pf in the rat CCD and IMCD.

AB - The objective of this study was to determine if the alpha-2 (α2) adrenoceptor agonist oxymetazoline would inhibit Pf in collecting duct nephron segments. The isolated perfused tubule technique was used to determine Pf by measuring net fluid flux in the presence of a lumen-to-bath osmotic gradient and by calculating Pf via standard equations. One set of studies was conducted using CCDs isolated from Sprague-Dawley rat kidneys and another set was conducted in terminal IMCDs isolated from Wistar rat kidneys. Experimental agents were added to the bathing solution, and all experiments were conducted at 37°C. Arginine vasopresein (AVP) at 220pM was used to increase Pf. Oxymetazoline and the α2 antagonist atipamezole were used at 1 μM. The sequence of periods and the results (Pf, μm/sec, mean±se) are shown below. Control AVP AVP+Oxy AVP+Oxy+Ati CCDs (n=7) -16±35 748±92* 295±113† 580±93® IMCPs (n=5) 3±1 140±6* 32±3* 76±3* *, † and ® - significantly different from the previous period (p<.001), (p<.005), and (p<.05), respectively. Oxy - oxymetazoline, Ati - atipamezole. We conclude that oxymetazoline, a partial α2A adrenoceptor agonist, inhibits AVP-stimulated Pf in the rat CCD and IMCD.

UR - http://www.scopus.com/inward/record.url?scp=33750132477&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:33750132477

VL - 11

JO - FASEB Journal

JF - FASEB Journal

SN - 0892-6638

IS - 3

ER -